NEW YORK, May 31 - Sangamo Biosciences's acquisition of Gendaq will allow the company to corner the market on zinc finger protein technology as well as to stave off any potential patent disputes, company executives said Thursday.

"Gendaq really represents the one piece of scientific thinking that was not part of our family," Casey Case, Sangamo's vice president for research, told GenomeWeb. "It's great to have them in the fold."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.